Rina Angela, Maffeo Debora, Minnai Francesca, Esposito Martina, Palmieri Maria, Serio Viola Bianca, Rosati Diletta, Mari Francesca, Frullanti Elisa, Colombo Francesca
Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, 53100 Siena, Italy.
UOC Laboratorio di Assistenza e Ricerca Traslazionale, Azienda Ospedaliero-Universitaria Senese, 53100 Siena, Italy.
Cancers (Basel). 2024 Aug 19;16(16):2882. doi: 10.3390/cancers16162882.
Lung cancer, including both non-small cell lung cancer and small cell lung cancer, remains the leading cause of cancer-related mortality worldwide, representing 18% of the total cancer deaths in 2020. Many patients are identified already at an advanced stage with metastatic disease and have a worsening prognosis. Recent advances in the genetic understanding of lung cancer have opened new avenues for personalized treatments and targeted therapies. This review examines the latest discoveries in the genetics of lung cancer, discusses key biomarkers, and analyzes current clinical therapies based on this genetic information. It will conclude with a discussion of future prospects and potential research directions.
肺癌，包括非小细胞肺癌和小细胞肺癌，仍然是全球癌症相关死亡的主要原因，占2020年癌症死亡总数的18%。许多患者在确诊时已处于晚期并伴有转移性疾病，预后较差。近年来，对肺癌遗传学的深入了解为个性化治疗和靶向治疗开辟了新途径。本文综述了肺癌遗传学的最新发现，讨论了关键生物标志物，并基于这些遗传信息分析了当前的临床治疗方法。最后将探讨未来前景和潜在的研究方向。
